Published in Cancer Res on March 02, 2010
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell (2010) 3.72
Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85
Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer (2011) 2.18
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
A tunable dual-promoter integrator for targeting of cancer cells. Mol Syst Biol (2010) 1.35
ATF3 is a novel regulator of mouse neutrophil migration. Blood (2014) 0.96
Functions of TAp63 and p53 in restraining the development of metastatic cancer. Oncogene (2013) 0.90
Human Oncoprotein MDM2 Up-regulates Expression of NF-κB2 Precursor p100 Conferring a Survival Advantage to Lung Cells. Genes Cancer (2011) 0.83
Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-β (TGF-β). J Biol Chem (2011) 0.81
The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling. Carcinogenesis (2015) 0.81
Upregulation of ATF-3 is correlated with prognosis and proliferation of laryngeal cancer by regulating Cyclin D1 expression. Int J Clin Exp Pathol (2013) 0.80
Inhibition of breast cancer invasion by TIS21(/BTG2/Pc3)-Akt1-Sp1-Nox4 pathway targeting actin nucleators, mDia genes. Oncogene (2015) 0.79
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading. BMC Cancer (2016) 0.79
B-cell translocation gene 2 mediates crosstalk between PI3K/Akt1 and NFκB pathways which enhances transcription of MnSOD by accelerating IκBα degradation in normal and cancer cells. Cell Commun Signal (2013) 0.77
Acquisition order of Ras and p53 gene alterations defines distinct adrenocortical tumor phenotypes. PLoS Genet (2012) 0.77
Cellular heterogeneity mediates inherent sensitivity-specificity tradeoff in cancer targeting by synthetic circuits. Proc Natl Acad Sci U S A (2016) 0.77
Tumor-promoting circuits that regulate a cancer-related chemokine cluster: dominance of inflammatory mediators over oncogenic alterations. Cancers (Basel) (2012) 0.76
The gain of function of p53 mutant p53S in promoting tumorigenesis by cross-talking with H-RasV12. Int J Biol Sci (2012) 0.76
HOP expression is regulated by p53 and RAS and characteristic of a cancer gene signature. Cell Stress Chaperones (2016) 0.75
Co-culture with lung cancer A549 cells promotes the proliferation and migration of mesenchymal stem cells derived from bone marrow. Exp Ther Med (2017) 0.75
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12
The H3K27 demethylase Utx regulates somatic and germ cell epigenetic reprogramming. Nature (2012) 2.80
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 2.74
Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 2.66
Activated K-Ras and H-Ras display different interactions with saturable nonraft sites at the surface of live cells. J Cell Biol (2002) 2.62
MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56
The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54
p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54
DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res (2003) 2.46
DNA methylation markers in colorectal cancer. Cancer Metastasis Rev (2010) 2.40
Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res (2004) 2.34
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
Individual palmitoyl residues serve distinct roles in H-ras trafficking, microlocalization, and signaling. Mol Cell Biol (2005) 2.24
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nat Genet (2012) 2.20
Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol (2006) 2.19
Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer (2011) 2.18
Three separable domains regulate GTP-dependent association of H-ras with the plasma membrane. Mol Cell Biol (2004) 2.09
Cell contact-dependent acquisition of cellular and viral nonautonomously encoded small RNAs. Genes Dev (2009) 2.07
A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res (2004) 2.06
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst (2006) 2.05
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol (2008) 2.04
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res (2002) 1.97
Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell (2010) 1.95
Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene (2004) 1.94
Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res (2002) 1.88
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res (2005) 1.86
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest (2003) 1.82
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol (2005) 1.80
Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res (2005) 1.80
Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res (2004) 1.76
Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem (2004) 1.76
Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res (2004) 1.74
A unique platform for H-Ras signaling involving clathrin-independent endocytosis. Mol Biol Cell (2007) 1.73
Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res (2005) 1.73
Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) (2006) 1.72
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol (2006) 1.69
Bone Gla protein increases HIF-1alpha-dependent glucose metabolism and induces cartilage and vascular calcification. Arterioscler Thromb Vasc Biol (2011) 1.69
Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A (2007) 1.68
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66
Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proc Natl Acad Sci U S A (2003) 1.66
Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res (2003) 1.65
Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res (2007) 1.64
Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res (2003) 1.64
Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol (2005) 1.63
Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.62
Studies on G-protein alpha.betagamma heterotrimer formation reveal a putative S-prenyl-binding site in the alpha subunit. Biochem J (2003) 1.61
The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Mol Syst Biol (2005) 1.60
Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med (2010) 1.60
Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res (2003) 1.59
Fine mapping of chromosome 3 in uveal melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1-p25.2. Cancer Res (2003) 1.59
Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res (2004) 1.59
p53, a novel regulator of lipid metabolism pathways. J Hepatol (2011) 1.58
Global DNA hypomethylation is associated with in utero exposure to cotinine and perfluorinated alkyl compounds. Epigenetics (2010) 1.57
p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One (2008) 1.55
Mitochondrial subversion in cancer. Cancer Prev Res (Phila) (2011) 1.54
Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One (2009) 1.54
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab (2004) 1.54
Quantitative detection of Merkel cell virus in human tissues and possible mode of transmission. Int J Cancer (2010) 1.53